SIGA Technologies Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SIGA Technologies, Inc. on September 25, 2006. The report discloses a material event involving PharmAthene, Inc., a subsidiary or related entity, regarding a significant government contract award.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The primary financial disclosure is the value of a new contract:
- Total Contract Value: Up to $213 million.
- Initial Funding Allocation: $34.7 million.
- Procurement Option: Department of Defense option to procure 90,000 doses of Protexia.
Material Changes
The material change reported is the award of a multi-year contract from the Department of Defense U.S. Army Space and Missile Command. This contract is for the advanced development of Protexia(R), a broad-spectrum chemical nerve agent prophylaxis (recombinant human butyrylcholinesterase). The initial stage covers manufacturing process development, preclinical safety testing, FDA Investigational New Drug (IND) submission, and Phase I clinical trial initiation.
Outlook and Management Commentary
Management indicates that following the successful completion of the Phase I clinical trial, the government may exercise options to fund additional development activities beyond the initial $34.7 million, potentially leading to FDA licensure. The contract positions the company to protect U.S. military personnel and civilians from chemical nerve agents.
Investor Verification Checklist
- Verify the legal relationship between SIGA Technologies, Inc. and PharmAthene, Inc. as described in the filing.
- Confirm the specific milestones required to unlock the remaining contract value beyond the initial $34.7 million.
- Review the attached press release (Exhibit 99.1) for detailed terms of the procurement option for 90,000 doses.
- Monitor future filings for the submission status of the Investigational New Drug (IND) Application.